Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for NTRK fusion-positive non-small-cell lung cancer, drawn from the whole corpus: 4 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Fusions are missed when only DNA panels are run.
Neurological side effects from TRK inhibition are class-wide.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Data specific to lung cancer come from small cohorts within basket trials.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 5 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
ORR 75% by independent review in the first 55 pooled patients across 17 tumour types.
A milestone in how this cancer is treated.